Clinical trials: Uterine Neoplasm
Endometrial Cancer
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy.
- Trial name
- TroFuse-005 (NCT06132958)
- Testing
- Sacituzumab tirumotecan, Doxorubicin, Paclitaxel
- Where
- 242 sites in United States, Argentina and 29 more
- Volunteers
- 710 people
- Sponsor
- Merck Sharp & Dohme LLC
Uterine Cervical Neoplasms, Uterine Cervical Dysplasia
Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention
Scientific Context High-risk types of human papillomavirus (HPV) are the causative agents for cervical cancer. Cervical cancer screening strategies rely on periodic Papanicolaou (Pap) testing.
- Trial name
- APACHE-1 (NCT01014026)
- Testing
- Screening test
- Where
- 5 sites in France
- Volunteers
- 734 people
- Sponsor
- University Hospital, Tours
Cervical Cancer, Human Papilloma Virus (HPV)
Using Plasma Human Papillomavirus (HPV)-Related Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) to Follow Response of Cervical Cancer to Surgery, Radiation, and Chemotherapy
The goal of this study is to test two commercially available technologies for their ability to detect treatment response in patients with cervical cancer following surgery, radiation, and chemotherapy: one based on polymerase…
- Trial name
- NCT07214584
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Florida
Myoma;Uterus
Laparoscopic Myomectomy With Morcellation or Transvaginal Extraction of Surgical Specimens.
Laparoscopic myomectomy represents the fertility-sparing gold standard approach for the management of subserosal and intramural uterine myomas: this technique allows faster recovery, less complications and improved surgical…
- Trial name
- MYMOTE-1 (NCT03570879)
- Testing
- Power morcellation, Transvaginal extraction
- Volunteers
- 250 people
- Sponsor
- Università degli Studi dell'Insubria
Endometrial Cancer
Adjuvant Stereotactic Pelvic Irradiation in Endometrial Cancer
Stereotactic Ablative Radiation (SABR/SBRT) will be prescribed to a dose of 30 Gy in 5 fractions, once weekly to the pelvis in post operative patients with endometrial cancer.
- Trial name
- ASPIRE (NCT04235179)
- Testing
- SABR
- Where
- Saudi Arabia
- Volunteers
- 30 people
- Sponsor
- King Saud University
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with recurrent or advanced endometrial cancer.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma
- Trial name
- NCT01307631
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Uterine Fibroids
PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata
This is a multicentre, Phase III, efficacy and safety open-label study with PGL4001 10mg once daily for 3 months, blinded towards the administration of progestin or placebo after end of PGL4001 treatment.
- Trial name
- PEARLIII (NCT01156857)
- Testing
- PGL4001, progestin
- Where
- 23 sites in Austria, Belgium and 2 more
- Volunteers
- 209 people
- Sponsor
- PregLem SA
Triple Negative Breast Cancer, Endometrial Cancer
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Background: The new drug ONC201 have been shown to kill breast cancer and endometrial cancer cells in the laboratory. The exact mechanism of action is not completely clear yet, but the ONC201 destroys the mitochondria inside the…
- Conditions
- Triple Negative Breast Cancer, Endometrial Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer
- Trial name
- NCT03394027
- Testing
- ONC201
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer
HPV Infection and Cervical Lesions in HIV Infected Women in Thailand: A Prospective Study
HIV-infected women are at high risk of developing cervical cancer. This is a 3-year cohort study nested in the already existing Program for HIV Prevention and Treatment (PHPT) cohort of HIV-infected patients in Thailand (NCT…
- Trial name
- PapilloV (NCT01792973)
- Where
- 24 sites in Thailand
- Volunteers
- 829 people
- Sponsor
- Institut de Recherche pour le Developpement
Endometrial Cancer
NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)
This is a German multi-center, prospective, non-interventional study (NIS) to collect real-world clinical data in patients with primary advanced (FIGO stage III or IV) or recurrent endometrial cancer (EC) receiving first-line…
- Trial name
- DUOLife (NCT06890273)
- Where
- 49 sites in Germany
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Cervical Cancer
DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating women who have advanced or…
- Trial name
- NCT00004866
- Testing
- exatecan mesylate
- Where
- 6 sites in United States
- Sponsor
- Daiichi Sankyo
Congenital Uterine Anomaly
Congenital Uterine Anomalies: Identifying Cancer Associations and Genetic and Environmental Factors to Improve Clinical Care
The purpose of this research study is to learn more about the health outcomes associated with congenital uterine anomalies (CUAs), and the possible environmental and genetic causes of the condition.
- Trial name
- NCT04661072
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Yale University
Tumor, Solid, Lung Cancer
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Independently developed by Sichuan Yingrui Pharmaceutical Technology Co., Ltd., CNSI-Fe is an innovative anti-cancer drug with Fe2+ as the active ingredient, which exerts anti-tumor effects by regulating the ferroptosis pathway.
- Conditions
- Tumor, Solid, Lung Cancer, Pancreas Cancer, Thyroid Cancer
- Trial name
- NCT07433283
- Testing
- Carbon Nanoparticle-Loaded Iron [CNSI-Fe], Carbon Nanoparticle-Loaded Iron
- Where
- 9 sites in China
- Volunteers
- 54 people
- Sponsor
- Sichuan Enray Pharmaceutical Sciences Company
Locally Advanced Cancer, Cervical Cancer
Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer
This is a mutlicentric, open-label non-randomized, national, 2-stage phase II trial to assess efficacy and safety of a weekly Carboplatin-Paclitaxel adjuvant chemotherapy after intensity modulated extended-field chemoradiation in…
- Trial name
- ACCRAPAN (NCT04016142)
- Testing
- Carboplatin-Paclitaxel adjuvant chemotherapy
- Where
- 6 sites in France
- Volunteers
- 21 people
- Sponsor
- Centre Oscar Lambret
Locally Advanced Cervical Carcinoma, Locally Advanced Colorectal Carcinoma
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
This phase I trial tests the safety and side effects of STIL101 for injection and how well it works in treating patients with pancreatic cancer, colorectal cancer (CRC), renal cell cancer (RCC), cervical cancer (CC) and melanoma…
- Conditions
- Locally Advanced Cervical Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma
- Trial name
- NCT06626256
- Testing
- Aldesleukin, Biopsy, Biospecimen Collection
- Sponsor
- City of Hope Medical Center
Cancer
THE EFFECT OF CANCER EDUCATION ON WOMEN'S AWARENESS LEVELS AND THEIR BEHAVIORS ON SCREENINGS
Disability is part of being human. He estimates that the prevalence of disability among women is 60% higher than that of men. Disabled women coexist in a dual state of vulnerability where "being a woman" and "being a disabled…
- Trial name
- NCT05881902
- Testing
- HEALTH FAITH MODEL GUIDED IN CANCER FREQUENTLY SEEN IN WOMEN EARLY DIAGNOSIS AND SCREENING METHODS EDUCATION, STANDART CANCER EDUCATİON
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yeşim KAYAPA
Cervical Carcinoma, Chemoradiotherapy
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
This study is a single-center, single-arm, open-phase II clinical study, the main purpose of which is to evaluate the effectiveness and safety of camrelizumab combined with concurrent chemoradiotherapy for early and locally…
- Conditions
- Cervical Carcinoma, Chemoradiotherapy, Anti-programmed Cell Death Receptor 1, Immunotherapy
- Trial name
- NCT05311566
- Testing
- Camrelizumab plus Concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Lei Li
Cervical Cancer Screening, Gynecologic Cancers
Compliance to Cervical Cancer Chemoradiation Guidelines: A Multicentric Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India
This is a combination of retrospective and prospective observational study that will be performed across NCG and other participating centers to report compliance to chemoradiation for cervical cancer.
- Conditions
- Cervical Cancer Screening, Gynecologic Cancers, Treatment Compliance, Chemoradiotherapy
- Trial name
- NCG-Compliance (NCT07290972)
- Testing
- Not applicable- observational study
- Where
- 2 sites in India
- Volunteers
- 618 people
- Sponsor
- Tata Memorial Hospital
Uterine Cervical Neoplasms
Clinical Evaluation of the BD Onclarity™ HPV Assay on the BD Viper™ LT System With Cervical Specimens
The purpose of the study is to compare the results of the Becton Dickinson (BD) Onclarity™ Human Papilloma Virus (HPV) Assay on the BD Viper™ LT instrument from liquid-based cytology (LBC) media diluted in BD HPV LBC diluent to…
- Trial name
- NCT01944722
- Testing
- BD Onclarity™ HPV assay on BD Viper™ LT, Colposcopy
- Where
- 41 sites in United States
- Volunteers
- 33,858 people, healthy volunteers welcome
- Sponsor
- Becton, Dickinson and Company
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.